Rexahn Pharmaceuticals Initiates Phase II Trial for Zoraxel(TM) to Treat Erectile Dysfunction

This multi-center proof is expected to be the works by the boundary of 2008. Chang H. Ahn, Chairman and Manager Executive Officer of Rexahn, noted, " We are too satisfied to publish the initiation of another Leaf II trial. Zoraxel TM testament prove itself a bounteous effective, less poisonous therapy for patients with erectile dysfunction.

Approximately Zoraxel TM Zoraxel TM is growth developed as an prompt proceeds tablet and has a well-established and choice safety profile, contradistinctive from ongoing essential PDE-5 inhibitors with diverse side stuff (priapism, severe hypotension, myocardial infarction, sudden death, increased intraocular force and sudden hearing loss).

Zoraxel & 8482; is a dual neurotransmitter enhancer in the brain, and thus, acts down the central basket case method that regulates sexual functions, whereas the PDE-5 inhibitors grind in the peripheral blood vessels and disturb particular erectile function.

In the example studies, Zoraxel TM has been shown to significantly come around all three functions of sexual activity, i.e. As such, Zoraxel TM may be a amassed forceful ED treatment for patients who are both responsive and unresponsive to PDE-5 inhibitors.

About Erectile Dysfunction (ED) ED is defined as the consistent inability to attain and advance an erection sufficient for passable sexual intercourse. It is estimated to modify up to 30 million men in the United States, with 52% of men between the ages of 40 and 70 reporting dispute with erectile function. By the year 2025, it is estimated that 322 million men worldwide will suffer from some measure of sexual dysfunction. Clinical administration of ED has progressed considerably in latest years.

The advancement of phosphodiesterase-5 (PDE-5) inhibitor therapeutics quickly followed the scientific patient of the nitric oxide (NO) signaling mechanism in erectile tissue. Adverse events affecting the vascular action compass been a dominant affliction with drugs that administer that response.

Investigations into the neurotransmission involved in penile erection, hormone actions involved in this response, and biochemical locution transduction processes within the erectile tissue, are indicative of denoting areas of scientific pursuit. About Rexahn Pharmaceuticals, Inc.

Rexahn's actual results may differ materially from the anticipated results and expectations expressed in these forward-looking statements as a decision of positive risks and uncertainties, including, Rexahn's distress of profitability, its auditor's going job qualification and the longing for supplementary central to drive its affair to mature its product candidates; the risk that Rexahn's system efforts relating to its product candidates may not be successful; the opportunity of existence unable to secure regulatory approval of Rexahn's product candidates; the risk that the results of clinical trials may not be completed on epoch or buttress Rexahn's claims; necessitate for and bazaar acceptance of Rexahn's narcotic candidates; Rexahn's reliance on third bee researchers and manufacturers to evolve its product candidates; Rexahn's expertise to develope and earn safeguard of its highbrow property; and other risk factors locate forth from generation to era in our filings with the Securities and Convert Commission.

These forward-looking statements are fabricated as of the day hereof; Rexahn assumes no debt to renew these forward-looking statements. Contacts Rexahn Pharmaceuticals, Inc. Beth Bittle, Communications Supervisor 240-268-5300, ext.